Cargando…
2363. Three-Month Safety and Immunogenicity of Bivalent SARS-CoV-2 Omicron-Containing Booster Vaccines: Interim Results From a Phase 3, Randomized, Observer-Blind, Active-Controlled Trial
BACKGROUND: Updated COVID-19 vaccines have been developed to help broaden protection against circulating SARS-CoV-2 variants. Here we present a 3-month interim analysis from a phase 3, randomized, observer-blind, active-controlled study of 2 omicron BA.1-containing vaccines: BA.1-monovalent mRNA-127...
Autores principales: | Lee, Ivan T, Cosgrove, Catherine A, Moore, Patrick, Bula, Marcin, Kalra, Philip, Dargan, Paul, Clark, Rebecca, Boffito, Marta, Sheridan, Ray, Bethune, Claire, Burns, Fiona, Saralaya, Dinesh, Nally, Rhiannon, Duncan, Christopher J A, Chadwick, David, Palfreeman, Adrian, Ramos, Alberto San Francisco, Heath, Paul T, Girard, Bethany, Sellers, Kristen, de Windt, Elizabeth, Sutherland, Andrea, Tracy, LaRee, Zhou, Honghong, Miller, Jacqueline, Priddy, Frances, Chalkias, Spyros, Das, Rituparna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677689/ http://dx.doi.org/10.1093/ofid/ofad500.1984 |
Ejemplares similares
-
PB2363: REPORTING LANGUAGE IN HAEMATOLOGICAL MALIGNANCIES
por: Watt, S., et al.
Publicado: (2022) -
Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022) -
2363 Inducing anti-tumor immunity in colorectal cancer
por: Mitchem, Jonathan B., et al.
Publicado: (2018) -
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
por: Chalkias, Spyros, et al.
Publicado: (2023) -
2363. Implementation of a Multi-Step Diagnostic Algorithm for C. difficile Infection
por: Walker, Morgan, et al.
Publicado: (2019)